| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss before income taxes | -19,417 | -15,095 | -14,089 | -12,954 |
| Income taxes | 0 | 0 | - | 7 |
| Net loss | -19,417 | -15,095 | -14,089 | -12,961 |
| Unrealized gain on marketable securities | 13 | -4 | -11 | 20 |
| Comprehensive loss | -19,404 | -15,099 | -14,100 | -12,941 |
| Basic, net loss per common share (in dollars per share) | -0.54 | -0.47 | -0.46 | -0.42 |
| Diluted, net loss per common share (in dollars per share) | -0.54 | -0.47 | -0.46 | -0.42 |
| Weighted average common shares outstanding, basic (in shares) | 35,749,160 | 31,930,665 | 30,711,872 | 30,632,347 |
| Weighted average common shares outstanding, diluted (in shares) | 35,749,160 | 31,930,665 | 30,711,872 | 30,632,347 |
Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. (VTGN)